KTRA Kintara Therapeutics Inc

Price (delayed)

$0.174

Market cap

$9.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.07

Enterprise value

$3.27M

Kintara Therapeutics, Inc. operates as a clinical and commercial stage drug development company with a focus on the treatment of cancer. The Company focuses on identifying clinical and commercial-stage compounds ...

Highlights
Kintara Therapeutics's EPS has soared by 62% YoY and by 32% from the previous quarter
Kintara Therapeutics's equity has soared by 56% YoY

Key stats

What are the main financial stats of KTRA
Market
Shares outstanding
55.3M
Market cap
$9.62M
Enterprise value
$3.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$9.42M
EBITDA
-$9.37M
Free cash flow
-$7.26M
Per share
EPS
-$4.07
Free cash flow per share
-$0.16
Book value per share
$0.15
Revenue per share
$0
TBVPS
$0.17
Balance sheet
Total assets
$7.45M
Total liabilities
$1.52M
Debt
$0
Equity
$5.92M
Working capital
$5.41M
Liquidity
Debt to equity
0
Current ratio
5.04
Quick ratio
4.74
Net debt/EBITDA
0.68
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-257.3%
Return on equity
-852.5%
Return on invested capital
N/A
Return on capital employed
-154.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KTRA stock price

How has the Kintara Therapeutics stock price performed over time
Intraday
4.57%
1 week
-3.44%
1 month
-16.98%
1 year
-95.82%
YTD
2.59%
QTD
-35.58%

Financial performance

How have Kintara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.42M
Net income
-$9.33M
Gross margin
N/A
Net margin
N/A
The net income rose by 44% YoY and by 12% QoQ
Kintara Therapeutics's operating income has increased by 44% YoY and by 11% QoQ

Growth

What is Kintara Therapeutics's growth rate over time

Valuation

What is Kintara Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kintara Therapeutics's EPS has soared by 62% YoY and by 32% from the previous quarter
The P/B is 73% lower than the 5-year quarterly average of 4.0
Kintara Therapeutics's equity has soared by 56% YoY

Efficiency

How efficient is Kintara Therapeutics business performance
KTRA's ROA has shrunk by 72% YoY but it is up by 16% QoQ
KTRA's return on equity has surged by 54% since the previous quarter

Dividends

What is KTRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KTRA.

Financial health

How did Kintara Therapeutics financials performed over time
The current ratio has surged by 133% year-on-year
Kintara Therapeutics's total liabilities has decreased by 48% YoY and by 26% from the previous quarter
The debt is 100% smaller than the equity
Kintara Therapeutics's equity has soared by 56% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.